Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)

Published:2020-10 Issue: Volume:138 Page:19-29
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tsai Hsiang-Lin,Huang Ching-Wen,Lin Yi-Wen,Wang Jui-Ho,Wu Chang-Chieh,Sung Yung-Chuan,Chen Tzu-Liang,Wang Hwei-Ming,Tang Hsiu-Chin,Chen Joe-Bin,Ke Tao-Wei,Tsai Chang-Sung,Huang Hsuan-Yuan,Wang Jaw-Yuan^ORCID

Funder

Pfizer

Roche

Ministry of Science and Technology

Ministry of Health and Welfare

Kaohsiung Medical University

Center for Cancer Research

Cohort Research Center

Taiwan Precision Medicine Initiative

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

3. Biologic therapies in the metastatic colorectal cancer treatment continuum—applying current evidence to clinical practice;Peeters;Canc Treat Rev,2012

4. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes;Iyer;J Clin Invest,1998

5. The role of UGT1A1∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer;Toffoli;J Clin Oncol,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and emerging strategies for irinotecan-induced diarrhea;European Journal of Pharmacology;2024-07

2. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer;The Oncologist;2024-06-05

3. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

4. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05

5. Recent Trends in Nanomaterial Based Electrochemical Sensors for Drug Detection: Considering Green Assessment;Current Topics in Medicinal Chemistry;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3